These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 10467325)

  • 1. A comparison of CD34+ cell selected and unselected autologous peripheral blood stem cell transplantation for multiple myeloma: a case controlled analysis.
    Gandhi M; Jestice H; Scott M; Bloxham D; Bass G; Craig J; Marcus R
    Bone Marrow Transplant; 1999 Aug; 24(4):369-75. PubMed ID: 10467325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
    Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral blood stem cell transplantation in myeloma using CD34 selected cells.
    Johnson RJ; Owen RG; Smith GM; Child JA; Galvin M; Newton LJ; Rawstron A; Major K; Woodhead V; Robinson F; Jack A; Morgan GJ
    Bone Marrow Transplant; 1996 May; 17(5):723-7. PubMed ID: 8733688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma.
    Harousseau JL; Attal M; Divine M; Milpied N; Marit G; Leblond V; Stoppa AM; Bourhis JH; Caillot D; Boasson M
    Bone Marrow Transplant; 1995 Jun; 15(6):963-9. PubMed ID: 7581098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome.
    Patriarca F; Damiani D; Fanin R; Grimaz S; Geromin A; Cerno M; Sperotto A; Silvestri F; Zaja F; Baccarani M
    Haematologica; 2000 Mar; 85(3):269-74. PubMed ID: 10702815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and molecular follow-up by amplification of the CDR-III IgH region in multiple myeloma patients after autologous transplantation of hematopoietic CD34+ stem cells.
    Martinelli G; Terragna C; Lemoli RM; Cavo M; Benni M; Motta MR; Amabile M; Ottaviani E; Testoni N; de Vivo A; Tura S
    Haematologica; 1999 May; 84(5):397-404. PubMed ID: 10329917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma.
    Schiller G; Vescio R; Freytes C; Spitzer G; Lee M; Wu CH; Cao J; Lee JC; Lichtenstein A; Lill M; Berenson R; Berenson J
    Bone Marrow Transplant; 1998 Jan; 21(2):141-5. PubMed ID: 9489630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent viral infections and delayed CD4+ cell recovery following CD34+ cell-selected autologous peripheral blood stem cell transplantation.
    Takeshima M; Takamatsu H; Iida M; Mochizuki Y; Okumura H; Yoshida T
    Int J Hematol; 1999 Oct; 70(3):193-9. PubMed ID: 10561914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation.
    Klaus J; Herrmann D; Breitkreutz I; Hegenbart U; Mazitschek U; Egerer G; Cremer FW; Lowenthal RM; Huesing J; Fruehauf S; Moehler T; Ho AD; Goldschmidt H
    Eur J Haematol; 2007 Jan; 78(1):21-8. PubMed ID: 17042762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT).
    Björkstrand B; Svensson H; Goldschmidt H; Ljungman P; Apperley J; Mandelli F; Marcus R; Boogaerts M; Alegre A; Remes K; Cornelissen JJ; Bladé J; Lenhoff S; Iriondo A; Carlson K; Volin L; Littlewood T; Goldstone AH; San Miguel J; Schattenberg A; Gahrton G
    Bone Marrow Transplant; 2001 Mar; 27(5):511-5. PubMed ID: 11313685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma.
    Wallington-Beddoe CT; Gottlieb DJ; Garvin F; Antonenas V; Sartor MM
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1386-93. PubMed ID: 19822297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Autologous transplantation of hematopoietic precursor cells following CD34 selection].
    Tichelli A; Gratwohl A; Bargetzi M; Nissen C; Wernli M; Herrmann R; Orth B; Signer E; Speck B
    Schweiz Med Wochenschr; 1996 Feb; 126(6):201-6. PubMed ID: 8720723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous transplantation of mobilized peripheral blood CD34+ cells selected by immunomagnetic procedures in patients with multiple myeloma.
    Abonour R; Scott KM; Kunkel LA; Robertson MJ; Hromas R; Graves V; Lazaridis EN; Cripe L; Gharpure V; Traycoff CM; Mills B; Srour EF; Cornetta K
    Bone Marrow Transplant; 1998 Nov; 22(10):957-63. PubMed ID: 9849692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [CD34+ cell dose and hematologic recovery in allogeneic peripheral blood stem cell transplantation].
    Sawada H; Wake A; Yamasaki Y; Izumi Y
    Rinsho Ketsueki; 2000 Jun; 41(6):500-6. PubMed ID: 10921350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD34+ selection of autologous peripheral blood stem cells for transplantation following sequential cycles of high-dose therapy and mobilization in multiple myeloma.
    Dyson PG; Horvath N; Joshua D; Barrow L; Van Holst NG; Brown R; Gibson J; To LB
    Bone Marrow Transplant; 2000 Jun; 25(11):1175-84. PubMed ID: 10849530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of stem cell mobilization regimen on lymphocyte collection yield in patients with multiple myeloma.
    Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
    Cytotherapy; 2008; 10(5):507-17. PubMed ID: 18608354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma.
    Reynolds C; Ratanatharathorn V; Adams P; Braun T; Silver S; Ayash L; Carson E; Eisbruch A; Dawson LA; McDonagh K; Ferrara J; Uberti J
    Bone Marrow Transplant; 2001 Apr; 27(8):801-7. PubMed ID: 11477436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-2-microglobulin level predicts outcome following autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
    Stella-Holowiecka B; Czerw T; Holowiecka-Goral A; Giebel S; Wojnar J; Holowiecki J
    Transplant Proc; 2007 Nov; 39(9):2893-7. PubMed ID: 18022010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
    Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
    Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.